Testing LM-101 Injection for Advanced Malignant Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and tolerability of LM-101 injection in patients with advanced malignant tumors. It aims to determine the Maximum Tolerated Dose (MTD) and the recommended phase 2 dose (RP2D) of LM-101, both as a standalone treatment and in combination with other therapies like Toripalimab and Rituximab. Participants will be closely monitored for their response and any adverse effects throughout the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
2. Aged ≥18 years old, male or female.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Life expectancy ≥ 3 months.
5. Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy.
6. At least one evaluable lesion.
7. Subjects in the combination therapy group must have Archived Samples or fresh tumor tissue specimens are required for testing.
8. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose:
9. Women of childbearing potential (WOCBP) must agree to use highly effective methods of contraception prior to study entry, during the study and for 6 months after the last dose of study drug.
10. Subjects who can communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria:

1. Subject has received prior investigational therapy directed at the same target therapy.
2. Subjects has participated in any other interventional clinical trial within 21 days prior to the first dosing of LM-101.
3. Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
4. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
5. Poorly controlled tumor-related pain.
6. Subjects with symptomatic/active central nervous system (CNS) metastases.
7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
8. Subjects with known hypersensitivity to antibody therapy.
9. Subjects who take systemic corticosteroids (\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medicationswithin 2 weeks prior to the first dosing of LM-101.
10. Subjects with the known history of autoimmune disease with the exception of subjects with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone.
11. Subject who has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
12. Use of any live attenuated vaccines within 28 days prior to the first dosing of LM-101.
13. Subjects who are using therapeutic doses of anticoagulants such as heparin or vitamin K antagonists.
14. Subjects who received major surgery or interventional treatment within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.).
15. Subjects who have history of severe cardiovascular disease.
16. Subjects who have uncontrolled or severe illness.
17. Subjects who have a history of immunodeficiency disease.
18. HIV infection, active tuberculosis or active HBV and HCV infection.
19. Subjects who have Known history of active tuberculosis.
20. Subjects who have other active invasive cancers, other than the one treated in this trial, within 5 years prior to screening.
21. Child-bearing potential female who have positive results in pregnancy test or are lactating.
22. Subject who have a known psychiatric diseases or disorders that may affect compliance with the trial.
23. Subject who is judged as not eligible to participate in this study by the investigator.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Zhongnan Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting
• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting
• Linyi Cancer Hospital
  Linyi, Shandong, China Not yet recruiting
• Beijing Tongren Hospital, CMU
  Beijing, China Terminated

Study contacts

• Study coordinator: Alex Yuan
• Email: alexyuan@lanovamed.com
• Phone: +8615901815211

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prognosis and molecular features of malignant tumors in adults

  This study tests how key molecular features relate to outcomes in adults with malignant tumors treated at a single hospital.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07622667

• 68Ga-FL-031 PET for diagnosing and staging cancer

  This project will test whether 68Ga-FL-031 PET imaging, compared with 18F-FDG PET, can detect and stage small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumors in adults.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301801

• LM-350 treatment for advanced solid tumors

  This trial will test LM-350, an experimental injectable drug, in adults with advanced solid tumors who have not responded to or cannot receive standard treatments.

  Recruiting at 3 sites Phase 1/2 LaNova Medicines Limited · Wollongong, New South Wales and 3 other locations · NCT07112222

• mRNA vaccine targeting KRAS-mutated cancers

  We will try an mRNA vaccine that targets KRAS mutations in adults with KRAS-mutated solid tumors, given alone or with the immunotherapy drug toripalimab and/or standard chemotherapy.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT07004244

• Testing SSS59 for advanced malignant tumors

  This study is testing a new treatment called SSS59 to see if it is safe and effective for people with advanced cancer.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Shanghai, Shanghai Municipality · NCT06944444

• Testing LM-299 for advanced malignant tumors

  This study is testing a new treatment called LM-299 to see if it is safe and can help people with advanced solid tumors that haven't responded to other therapies.

  Recruiting Phase 1/2 LaNova Medicines Limited · Perth, Western Australia and 5 other locations · NCT06650566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.